ATORVASTATIN
Atropine sulfate is an anticholinergic that blocks muscarinic receptors, reducing secretions and increasing heart rate. Used in bradycardia and preanesthesia. Side effects include dry mouth, blurred vision, urinary retention, and tachycardia. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of action
Atorvastatin is a synthetic lipid-lowering agent of the statin class that competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. Inhibition decreases intrahepatic cholesterol levels, leading to upregulation of LDL receptors on hepatocytes and enhanced clearance of circulating LDL particles. It also modestly affects VLDL and triglyceride metabolism and may exert pleiotropic effects on endothelial function and inflammation.
Benefits and advantages
Atorvastatin is one of the most widely used statins and is fundamental in atherosclerosis research, lipid metabolism studies, cardiovascular outcome modelling and investigations into statin pleiotropy (including endothelial nitric oxide synthase regulation and plaque stabilisation). Its well-characterised pharmacokinetics make it ideal as a benchmark compound in drugdrug interaction and transporter studies (e.g., OATP1B1).
Side effects and risks
Adverse effects include myalgia, elevated creatine kinase, rare rhabdomyolysis, hepatic transaminase elevations and gastrointestinal symptoms. There are important interactions with drugs that share metabolic pathways (notably CYP3A4) or hepatic uptake transporters. In raw-material form, atorvastatin should be handled as a potent enzyme inhibitor with appropriate dust and exposure control.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C33H35FN2O5 |
|---|---|
| Molecular Weight | 558.6 g/mol |
| CAS Number | 134523-00-5 |
| Storage Condition | Keep container tightly closed in a dry and well-ventilated place. Light sensitive. /Atorvastatin calcium salt trihydrate/ |
| Solubility | Practically insoluble |
| Purity | Purity information is available upon request (COA). |
| Synonym | atorvastatin; 134523-00-5; Cardyl; atorvastatina; atorvastatine |
| IUPAC/Chemical Name | (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid |
| InChl Key | XUKUURHRXDUEBC-KAYWLYCHSA-N |
| InChl Code | InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
